Truist analyst David MacDonald lowered the firm’s price target on Walgreens Boots Alliance to $40 from $42 and keeps a Hold rating on the shares. The company’s Q2 results were "solid" on the top and bottom lines, with Pharmacy and Retail trends remaining solid despite a lingering COVID headwind, the analyst tells investors in a research note. Truist remains neutral on Walgreens to reflect market multiples however, though its model is "under review".
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on WBA:
- Walgreens Boots Alliance Inc. Earnings Update: Did it Beat Estimate Forecasts?
- Walgreens In the Green on Q2 Beat
- Walgreens Boots reaffirms FY23 adjusted EPS view $4.45-$4.65, consensus $4.51
- Walgreens Boots Alliance reports Q2 adjusted EPS $1.16, consensus $1.10
- Notable companies reporting before tomorrow’s open
